Skip to main content

Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377

Social Author Name
Dr. John Cush
Tweet Content
Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK

Potential new treatment for Sjogren's Is there finally something new on the horizon in Sjogren’s syndrome? Dr. E

Social Author Name
Dr. John Cush
Tweet Content
Potential new treatment for Sjogren's Is there finally something new on the horizon in Sjogren’s syndrome? Dr. Eric Dein. ( @ericdeinmd) discusses studies presented at #ACR22. https://t.co/YinEPKlJb2 https://t.co/YOsc159GFt

Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases

Social Author Name
Dr. John Cush
Tweet Content
Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more. https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y

SLE, Sex and STDs Once in a while, I find an abstract at the American College of Rheumatology meeting that can potenti

Social Author Name
Dr. John Cush
Tweet Content
SLE, Sex and STDs Once in a while, I find an abstract at the American College of Rheumatology meeting that can potentially save lives and be implemented in practice now. Dr. Dao ( @KDAO2011) discusses abstract #0939 presented at #ACR22. https://t.co/0DtAgzB41G https://t.co/O1z7J0O4c6
Will a vegetarian diet and exercise actually help RA disease activity?
The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was less well delineated.

New Treatments for SLE? Dr. Petri discusses abstract 1117 presented at #ACR22. Efficacy & Safety of Deucravacitini

Social Author Name
Dr. John Cush
Tweet Content
New Treatments for SLE? Dr. Petri discusses abstract 1117 presented at #ACR22. Efficacy & Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients w/Active SLE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study https://t.co/nKOserLdbb https://t.co/xhVsxT8BZW

RA Topic Panel RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, N

Social Author Name
Dr. John Cush
Tweet Content
RA Topic Panel RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan https://t.co/GMqRmF2yXA https://t.co/WmYRTp49Rv
Subscribe to
×